Ajanta Pharma Ltd

BSE: 532331 | NSE: AJANTPHARM | ISIN: INE031B01031 
Market Cap: [Rs.Cr.] 5,996.52 | Face Value: [Rs.] 5
Industry: Pharmaceuticals - Indian - Formulations

Company Profile

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacture and marketing of quality finished dosages in domestic and international markets. Established in 1973 and headquartered in Mumbai-India, it has a mission of 'Serving Global Health Care Needs Worldwide'. Ajanta has been consistently providing affordable and quality medicines to patients in different parts of the world. The company began its operation in the year 1973 by setting up a small repackaging unit. The company also launched 4 products under its own brand name for repackaged pharma items in the same year. In 1979, the Company set up compact Manufacturing factory in Chikalthana, Maharashtra and also launched 1st own manufactured OTC product- Pinkoo Gripe Water, making a mark in the industry by deviating from easy path of following leaders in gripe water industry. A New Manufacturing Facility was built by the company in the year 1984 in Paithan and the company also entered in institutional business. During the period between 1995 to 1998, the company established dedicated R&D facility at Kandivli and also set up manufacturing facilities in Mauritius and CIS. In 2000, the company went public with shares by listing shares in BSE and NSE and also undertook major expansion of manufacturing facilities. In 2002, the company entered domestic prescription market with speciality segment force. In 2007, the company expanded its R&D facility with independent premises in Kandivali. The company also got USFDA Approval for its paithan manufacturing facility in 2008. In 2009, the company started Active Pharmaceutical Ingredient (API) plant in Waluj, Aurangabad for captive use. Ajanta's financial performance has been outstanding with cumulative growth of 23% in revenue and 56% in profit during 10 financial years ending March 2013. Today, Ajanta has leading brands in India and globally. The brands which have made their mark, attained leadership position and brought accolades to the organization. Today Ajanta has more than 1500 product registrations worldwide and a basket of 200+ products. Today the company employs 4,000 people worldwide and the products are sold in over 30 countries. The company also operates with 5 state-of-the art manufacturing facilities that produces high quality pharmaceutical products. In India, the company has a significant presence in the fast growing specialty therapeutic segments of cardiology, dermatology, ophthalmology and musculoskeletal. With primary focus on new product innovation and introduction. the company has been consistently identifying unmet medical needs and introducing many first-to-market products to cater to those needs. The companies products provide patient compliance and convenience over existing therapeutic options. Gaining first mover advantage, many of the companies brands hold leadership positions in their respective sub- therapeutic segments. Ajanta has significant presence in many countries in Asia, Africa and Latin America with customized product portfolio to suit the needs of each country. Having successfully gone through US FDA inspection for one of the products, the company has started commercial shipments to USA since March 2013. With a portfolio of 14 ANDAs which have been filed with the US FDA, the company looks forward to the US market to be the key growth driver in coming years. The company has a advanced Research & Development Centre for API synthesis and finished formulations of different dosage forms. Advent', our R&D centre has a team of over 300 scientists working on innovative products for various markets across the globe. The company has acquired strong capabilities for developing generic formulations and process chemistry over the years.

Futures & Options Quote
Future Data Not present
Key Information

Key Executives:

Mannalal B Agrawal , Chairman

Purushottam B Agrawal , Vice Chairman

Madhusudan B Agrawal , Vice Chairman

Yogesh M Agrawal , Managing Director


Company Head Office / Quarters:

Ajanta House,
Charkop Kandivli (W),
Mumbai,
Maharashtra-400067
Phone : Maharashtra-91-022-66061000/1204/1203 / Maharashtra-
Fax : Maharashtra-91-022-66061200/1300 / Maharashtra-
E-mail : nikhil.bhatt@ajantapharma.com
Web : http://www.ajantapharma.com

Registrars:


 
Fund Holding
 
 
Better Investment Avenue

Check whether Taxed / Tax free investment avenue is better for you

  Taxed Avenue Tax-Free Avenue
Investment amount (Rs.)  
Tenure of Investment (years)  
Interest earned (% p.a)
Compounded every
Your tax bracket (%)